Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukaemia.Leukemia & Lymphoma. 2021; (Dec 31): 1-4
- Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma.N Engl J Med. 2022; 386 (Feb 17 Epub 2021 Dec 11. PMID: 34891224): 640-654
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma (BELINDA).N Engl J Med. 2022; 386 (Feb 17 Epub 2021 Dec 14): 629-639
- IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.BMC Med Res Methodol. 2021; 21 (Jun 1 PMID: 34074267): 111
- Synthetizing published evidence on survival by reconstruction of patient-level data and generation of a multi-trial Kaplan-Meier curve.Cureus. 2021; 13 (Nov 9 PMID: 34786276): e19422
- Medical therapy, radiofrequency ablation, or cryoballoon ablation as first-line treatment for paroxysmal atrial fibrillation: interpreting efficacy through the Shiny method.Cureus. 2022; 14 (Feb 27): e22645
- Long-term progression-free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons.Eur J Haematol. 2022; (Oct 3 Epub ahead of print. PMID: 36193009)
- Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N Engl J Med. 2017; 377 (Dec 28 Epub 2017 Dec 10. PMID: 29226797; PMCID: PMC5882485): 2531-2544
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol. 2019; 20 (Jan Epub 2018 Dec 2. PMID: 30518502; PMCID: PMC6733402): 31-42
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.Lancet Oncol. 2021; (Oct;22 Epub 2021 Sep 10. PMID: 34516954): 1403-1415
- Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.J Hematol Oncol. 2021; 14 (Sep 8 PMID: 34493319; PMCID: PMC8425084): 140
- CAR T-cell therapy for large B-cell lymphoma—who, when, and how?.N Engl J Med. 2022; 386 (Feb 17 Epub 2021 Dec 14. PMID: 34904797): 692-696